CN108893473A - RAB23 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells - Google Patents

RAB23 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells Download PDF

Info

Publication number
CN108893473A
CN108893473A CN201810830035.6A CN201810830035A CN108893473A CN 108893473 A CN108893473 A CN 108893473A CN 201810830035 A CN201810830035 A CN 201810830035A CN 108893473 A CN108893473 A CN 108893473A
Authority
CN
China
Prior art keywords
stem cells
rab23
epidermal stem
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810830035.6A
Other languages
Chinese (zh)
Other versions
CN108893473B (en
Inventor
杨骏
朱成光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Yuan Kangrui Biological Technology Co.,Ltd.
Original Assignee
Luoyang Xuan Zhi Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoyang Xuan Zhi Biological Technology Co Ltd filed Critical Luoyang Xuan Zhi Biological Technology Co Ltd
Priority to CN201810830035.6A priority Critical patent/CN108893473B/en
Publication of CN108893473A publication Critical patent/CN108893473A/en
Application granted granted Critical
Publication of CN108893473B publication Critical patent/CN108893473B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

RAB23 gene editing is carried out for epidermal stem cells using CRISPR-Cas system the present invention provides a kind of, the follow-up study more particularly to a kind of foundation of epidermal stem cells cell line for constructing RAB23 gene knockout, for Skin Squamous Cell Carcinoma.A special gRNA is wherein constructed and obtained, the gene editing efficiency that CRISPR/Cas9 in epidermal stem cells is directed to RAB23 can be significantly improved.Epidermal stem cells RAB23 provided by the invention, which knocks out plasmid, has preferable genetic stability and higher target practice efficiency.

Description

RAB23 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
Technical field
The present invention provide it is a kind of using CRISPR-Cas system for epidermal stem cells carry out RAB23 gene editing, especially It is to be related to a kind of foundation of epidermal stem cells cell line for constructing RAB23 gene knockout.
Background technique
Epidermal stem cells (Epidermal stem cells, EpiSCS) are with self duplication and multi-lineage potential Stem cell, its normal proliferative and differentiation be maintain skin and its appendicle (sweat gland hair, sebaceous glands) structure and function it is complete The basic demand of whole property.In physiological conditions, epidermal stem cells are divided into a stem cell and one by Asymmetric division mode A transit amplifying cells (transit amplifying cellsTA cell), TA cell after multiple division using being divided into Postmitotic cells (Post-mitotic cells) and terminally differentiated cells (terminally-differentiated Cells), to supplement the needs that epidermal cell is constantly updated.Research shows that epidermal stem cells can not only be trained Long Term Passages in vitro Support, and keep its Proliferation, Differentiation potential (Dunnwald et al, Exp Dermatol, 2001,10：45-54.Papini et Al.stem cells, 2003,21：481-494), moreover, also being shown under the conditions of certain environment similar to embryonic stem cell Differentiation potential [Liang et al, stem cells, 2002：20：21-31].Therefore, the epidermal stem cells of purifying are obtained not Only seed cell can be provided to be built with the artificial skin of physiological function, and can be used for gene therapy and transgenic animals Production.
Human pluripotent stem cell (Human pluripotent stem cells, hPSCs) and genome editing technique knot Established cell model is closed, provides a unique experiment porch for disease research.Utilize this platform system, research Personnel can study specific gene mutation even chromosomal structural variation to mankind's various kinds of cell type and tissue organ function Influence and its detailed molecular mechanism, and " personalization " disease model for carrying different genetic mutations can be established for extensive Drug screening.The foundation of the model system has benefited from genome editing technique, especially CRISPR/Cas9 (Clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins9, CRISPR/Cas9) the rapid development of technology.
Rab23 is RAS proto-oncogene member, and the albumen of coding is Small GTPases superfamily Rab family member, mutation Mouse can be caused to open brain syndrome (open brain syndrome), therefore also known as opb gene.2001, Eggenschwile:Deng the study found that Rab23 is the necessary negative regulatory factor of Sonic Hedgehog signal path, and it is close several Year, Rab23 is increasingly paid attention to by scholar as the effect of proto-oncogene.The study found that Rab23 participate in liver cancer, gastric cancer, lung cancer, The occurrence and development of breast cancer and thyroid cancer, and discovery is closely related with tumor invasion for the first time in gastric cancer.
Wherein especially cutaneous squamous cell carcinoma (cutaneous squamous cell carcinoma, c SCC) is one Malignant tumour of the kind originating from epidermis, cutaneous appendages and stratified squamous epithelium keratinocyte, morbidity account for skin evil The 16% of property tumour, is only second to basal-cell carcinoma, actinic keratosis, bowen's disease and keratoacanthoma can lead to cutin shape At the malignant proliferation of cell.C SCC has invasion, can occur to shift in early days.Therefore, the high of squamous cell carcinoma shifts, easily invades Attacking property is the public health problem for threatening the global people, further studies Skin Squamous Cell Carcinoma and invades mechanism, transfer and value-added point Handset system has important value and profound significance.And Rab23 high expression in squamous carcinoma, and break up negative correlation with squamous carcinoma； Transwell experiment confirms that Rab23 remarkably promotes squamous cell carcinoma invasion, and regulates and controls the expression of invasion key molecule Rac1.
Versatility based on epidermal stem cells, in order to which the epidermal stem cells for studying knockout RAB23 gene are thin in cutaneous squamous The function of born of the same parents' cancer treatment aspect, the epidermal stem cells cell line for establishing knockout RAB23 gene become particularly important.
Summary of the invention
The object of the present invention is to provide a kind of epidermal stem cells for knocking out RAB23 gene, and effectively overcoming the prior art makes The technological deficiency of heredity cannot be stablized by carrying out interference with siRNA.
To achieve the above object, the present invention provides a kind of target of CRISPR-cas system, according to the gene sequence of RAB23 Column, the specific sgRNA of design are as follows：
RAB23-sgRNA1：5'to 3'attacaaaggcctactatcg
RAB23-sgRNA2：5'to 3'agtcactccggtcagaattc.
To achieve the above object, the present invention provides a kind of raising CRISPR-cas system and knocks out in epidermal stem cells The method of RAB23 gene, including synergistic protein is introduced into host cell, the synergistic protein ESCS-higher is by SEQ ID NO:Nucleotide sequence coded protein shown in 1.
Further, the synergistic protein is comprising a) or b)：
a)SEQ ID NO:The polynucleotide sequence of nucleotide sequence coded protein shown in 1；
b)SEQ ID NO:Amino acid sequence shown in 2.
Further, a kind of system carrying out gene editing using CRISPR/Cas9 in epidermal stem cells is provided, It is characterized in that the system comprises：(1) for expressing SEQ ID NO：The plasmid of ESCS-higher described in 1；(2) The plasmid for the expression PX330 that sgRNA is already inserted into (it can express sgRNA and cas9).
Further, sgRNA the and cas9 expression vector is also possible to other expression vectors commonly used in the art.
The method that the present invention provides a kind of to use CRISPR/Cas9 gene editing RAB23 in epidermal stem cells, this Invention has the following advantages that：
The present invention provides by gRNA design and optimization nearly 100 times, obtaining can be special in epidermal stem cells Property the 2 specific gRNA knocked out for RAB23 gene, there is stronger knockout effect, and the present invention is in table In skin stem cell, the cell line of RAB23 gene knockout is constructed, screens and optimizes and obtain optimal sgRNA, knocks out efficiency Height, passage are stablized.
Detailed description of the invention
Fig. 1 Western-blot detects RAB23 protein expression result figure；4 be epidermal stem cells blank control；3 be not lead Enter the effect of the gRNA2 of synergistic protein；1 is the effect for importing the gRNA1 of synergistic protein；2 be not import synergistic protein The effect of gRNA1.
Below by embodiment, technical scheme of the present invention will be described in further detail.
Specific embodiment
Further illustrate that the present invention improves the technical side of the method for genome editorial efficiency below by specific embodiment Case.
The building of embodiment 1, CRISPR expression vector
The design of gRNA
According to the gene order of target gene, by applicant's early period, optimization design is specifically screened from tens gRNA Form to specific sgRNA is as follows：
RAB23-sgRNA1：5'to 3'attacaaaggcctactatcg
RAB23-sgRNA2：5'to 3'agtcactccggtcagaattc.
According to above-mentioned gRNA, positive oligonucleotide sequence is obtained plus CACC at its end 5', at the end 5' of its complementary strand In addition AAAC obtains reverse oligonucleotide sequence, it is respectively synthesized forward and reverse oligonucleotide sequence, then by the sequence of synthesis Denaturation, annealing, obtain the double chain DNA fragment with BbsI cohesive end, as follows：It is positive：5'- CACCNNNNNNNNNNNNNNNNNNNN is reversed：
NNNNNNNNNNNNNNNNNNNNCAAA-5 ', denaturation, annealing system are：2 μ l forward direction oligonucleotide chains (50 μM) 2 46 μ l l*NEB buffer of μ l reverse oligonucleotide chain (50 μM) is run in PCR instrument by following procedure：90 DEG C, 4min；72 DEG C, 10min；37 DEG C, 22min；25 DEG C, 25min.
Double chain oligonucleotide chain after annealing contains the cohesive end of BbsI, directly and by the pX330- of BbsI digestion U6-Chimeric_BB-CBh-hSpCas9 (hereinafter referred to as PX330) carrier is attached, and can obtain PX330-gRNA-Cas9 Recombinant plasmid.
Digestion system：39.3 μ l, 10*FD buffer of water, 52 3.7 37 DEG C of water-baths of μ l (2 μ g) of μ l, PX330 of μ l, BbsI Plasmid after 2h digestion is directly recycled with plastic recovery kit.
Linked system：0.5 μ l of annealed product, the PX330 plasmid 2 μ l of 2 μ 1,5*ligation buffer of linearisation, T4DNA Ligase (3units/ μ 1), 1 μ l, the connection product that water 4.5 μ l, 16 DEG C of water-bath 2h obtain above-mentioned steps convert JM109 competent cell is coated on the LB plate of Amp+, and picking positive colony connects bacterium, and 37 DEG C of shaking tables shake bacterium and stay overnight, and plasmid is taken out Extraction reagent kit extracts plasmid and carries out sequencing identification, obtains PX330-gRNA plasmid.
Embodiment 2 clones synergistic protein ESCS-higher and carrier construction
Synergistic protein ESCS-higher gene is cloned, by full genome synthetic method, obtains SEQ ID NO：Described in 1 Gene order using the sequence as template be respectively 5'-atgatatactttattagaat- according to upstream and downstream primer sequence 3', 5'-tcaagggatttccatttctc-3', primer and full-length genome are synthesized by Shanghai Sheng Gong Co., Ltd.PCR reaction is expanded Increase ESCS-higher gene target gene fragment, amplification reaction system is as follows:95 DEG C, 40s, 57 DEG C, 1min, 72 DEG C, 1min, 72 DEG C, 10min, recycle 35 times, PCR product is sequenced by Shanghai Sheng Gong Co., Ltd, by sequencing, in conjunction with SEQ ID NO：1 exact matching.Then, the target gene of PCR amplification is connected to empty carrier slow virus carrier pHIV-CS-CDF-CG- On PRE, recombined lentivirus vector is identified by the methods of PCR amplification, digestion, sequencing.In conjunction with proof recombined lentivirus vector It constructs successfully.Then by the recombined lentivirus vector plasmid with helper plasmid together coinfection epidermal stem cells (ESCs) (according to Method of claim 1 is separately cultured acquisition in CN1253558C), ESCS-higher base can be expressed by being packaged by recombination The epidermal stem cells of cause.By PCR screening and identification, the stem cell of stable transfection is used for subsequent gene editor application.
Applied analysis of 3 CRISPR/Cas9 of embodiment in epidermal stem cells
SgRNA expression plasmid prepared by embodiment 1, well known Cas9 expression plasmid cotransfection epidermal stem cells.Using The transfection epidermal stem cells rotaring redyeing system and reagent that build are made Lipofectamine by lipofectionTM2000 (invitrogen company), transfection detailed step is referring to transfection specification.With the dry thin of the synergy gene of untransfected embodiment 2 Born of the same parents are as positive control.
4 Western-blot of embodiment detects RAB23 protein expression situation
1. total protein extraction
Cultivate cell cracking
(1) by epidermal stem cells attached cell, culture solution is removed, is washed one time with PBS, suspension cell is collected by centrifugation, PBS It washes one time.
(2) usually every 106 cells can add 0.1ml RIPA buffer, and lysate and cell come into full contact with.
(3) it places on ice several minutes, is gently blown and beaten with pipette tips, crack cell sufficiently, then gently inclination culture dish makes to split Solution product flow to bottle ware one side or one jiao, it is then transferred to 1.5ml centrifuge tube, acutely oscillation 30 seconds.
DEG C centrifugation of (4) 12,000 × g, 45 minutes, takes supernatant, and it is heavy can to carry out subsequent electrophoresis, Western or immune It forms sediment and operates.
Tissue block cracking
(1) tissue cuts into tiny fragment.1ml RIPA lysate is added in every 100 milligrams of tissues.Use glass homogenizer Homogenate homogenate 20 times manually up and down.
(2) homogenate is transferred to 1.5ml centrifuge tube.
DEG C centrifugation of (3) 12,000 × g, 45 minutes, takes supernatant, and it is heavy can to carry out subsequent electrophoresis, Western or immune It forms sediment and operates.
2. determination of protein concentration (BCA surveys protein concentration)
The preparation of working solution
(1) before measuring, according to BCA Reagent A:BCA Reagent B=100:Work is configured to after 1 ratio mixing When making liquid, such as preparing the working solution of 30ml, the BCA Reagent B of 0.3ml is added in the BCA Reagent A of 30ml Afterwards, the working solution sufficiently after oscillation mixture system can be saved three days at 4 DEG C and be used.
(2) calculation method of work liquid measure needed for is as follows：
Required working solution total volume (ml)=[(8 parts of BSA standard solution or 7 parts+test sample number) × parallel samples number (n)+1] × 1 working solution volume needed for sample
Example) Standard Operating Procedure【1ml reaction system】When test sample number is 12, Duplicate Samples (n=2)：
[(8+12) × 2+1] × 1ml=41ml
Example) Standard Operating Procedure【200 μ l reaction systems】, test sample number be 20, Duplicate Samples (n=2) when： [(8+ 20) × 2+1] × 0.2ml=11.4ml
Example) low concentration protein example measurement operating process【1ml reaction system】, test sample number be 12, it is parallel When sample (n=2)：[(7+12) × 2+1] × 0.5ml=19.5ml
3. Standard Operating Procedure (the quantification range of low concentration protein sample：0~200 μ g/ml)
【0.2ml reaction system is measured using microwell plate】
1) preparation of BSA standard solution.
(1) preparation of 0.2mg/ml BSA standard solution：Take 120 μ l BSA Standard Solution (2 mg/ Ml), it is sufficiently mixed after 1,080 μ l dilution being added.
(2) according to different concentration dilution BSA standard solutions, the dilution of BSA standard solution and test sample can make With deionized water, 0.9%NaCl or PBS.
2) preparation of BSA standard curve
(1) the BSA standard solution after taking 100 μ l to dilute respectively is added in microwell plate, each concentration take 2 it is parallel Sample.
(2) it after 100ul working solution being added, mixes immediately.
It reacts after sixty minutes, is cooled to room temperature in (3) 37 DEG C of water baths.
(4) using the absorbance value at spectrophotometric determination 562nm.When measurement, using 1mL cuvette, with water school Zero.Detection finishes all samples as far as possible in 20 minutes.
(5) absorbance value of each concentration BSA standard solution subtracts the average value of Blank value, and it is molten to draw BSA standard items The standard curve of liquid.
3) measurement of test sample
When test sample measures, it is proposed that be measured simultaneously with BSA standard solution.
(1) 100 μ l test samples are taken to be added in microwell plate respectively, each sample takes 2 Duplicate Samples to be measured.
(being measured after dilution process dilution test sample identical with BSA standard solution if necessary, also may be selected)
(2) it after 100 μ l working solutions being added, mixes immediately.
It reacts after sixty minutes, is cooled to room temperature in (3) 37 DEG C of water-baths.
(4) microplate reader wavelength is set at 562nm and is measured.With water school zero.It detects and finishes in 20 minutes as far as possible All samples.
(5) absorbance value of each sample solution subtracts the average value of Blank value, calculates detection sample according to standard curve The protein concentration of product.
4.SDS-PAGE electrophoresis
(1) clamping in folder is put into after glass plate alignment.Then vertical card prepares encapsulating on the top of the shelf.
(2) 10% separation gel is prepared, shaking up immediately after addition TEMED can encapsulating.
(3) when having a fringence between Dang Shui and glue, illustrate that glue has coagulated.Waiting 3min to solidify glue sufficiently again can It removes photoresist and upper water and is blotted water with blotting paper.
(4) 4% concentration glue is prepared, shaking up immediately after addition TEMED can encapsulating.Remaining space is filled into concentration glue Then comb is inserted into concentration glue.
(5) it is rinsed with water and glue is concentrated, put it into electrophoresis tank.(small glass-board surface is inside, big glass-board surface to Outside.If only running one piece of glue, that slot another side will pad one piece of plastic plate and have facing out on one side for word.) (6) taking-up loading sample 4 are pressed with 5 × SDS sample-loading buffer：The mixing of 1 ratio, boiling 5min in boiling water after mixing makes albuminous degeneration.
(7) plus after enough electrophoresis liquids equal protein loading is pressed.
(8) electrophoresis, conversion voltage was gone to offset plate bottom to bromjophenol blue and was not run just to 120V after 80V runs concentration glue Out.
(9) opening clip keeps black one side holding horizontal, is successively padding foam-rubber cushion, filter paper, glue, PVDF film (warp above Methanol activation), filter paper, foam-rubber cushion；Change electrophoresis liquid into transfer liquid simultaneously.
(10) electric current is adjusted to constant current 200mA, shifted about 1 hour.
(11) film is taken out, and carries out front and back sides label, cleans 1 minute in TBST, is then closed with confining liquid.
(12) corresponding primary antibody is diluted to certain concentration (1 with confining liquid:500), the dilution final concentration of internal reference primary antibody It is 1：3000, it then incubates 1.5 hours or 4 DEG C and is incubated overnight.
(13) it is cleaned 3 times, every time 5 minutes with TBST.
(14) secondary antibody is diluted to certain concentration (1 with confining liquid:3000) it, then incubates 1.5 hours.
(15) it is cleaned 4 times, every time 5 minutes with TBST.
5. chemiluminescence is developed, fixing
(1) two kinds of reagents of A and B are in vitro mixed in equal volume, is then added in the front of pvdf membrane, incubate general 2 points Clock.
(2) enter darkroom, one layer of preservative film of pvdf membrane upper cover wipes extra luminous agent.Film is pressed in preservative film On, the different time for exposure is selected according to luminous intensity.
(3) film is put into developer solution, after there is band, is immediately placed in fixing solution, flowing water dries in the air after developing photographic film It is dry.
(4) film is scanned, then analyzes purpose item with UVP gel images processing system Labworks4.6 software The gray value of band.
(5) RAB23 protein expression in epidermal stem cells after transfection is detected by Western-blot, as a result As shown in Figure 1, epidermal stem cells blank control, protein expression are not affected；The gRNA1 for not importing synergistic protein can Target gene is knocked out, protein expression can be preferably suppressed, and inhibiting rate reaches 88.9%；And import synergistic protein GRNA1 has the gene knockout effect albumen inhibiting rate that increases significantly and reaches 99.7%；Do not import the gRNA2's of synergistic protein Protein expression inhibiting rate reaches 33.2%, and effect is not significant.This absolutely proves that gRNA1 is as applicant from tens gRNA The preferable gRNA that selection disease optimization obtains has fabulous application prospect and application value.
It should be noted last that the above examples are only used to illustrate the technical scheme of the present invention and are not limiting, although ginseng It is described the invention in detail according to preferred embodiment, those skilled in the art should understand that, it can be to the present invention Technical solution be modified or replaced equivalently, without departing from the spirit and scope of the technical solution of the present invention.
Sequence table
<110>Luoyang Xuan Zhi Biotechnology Co., Ltd
<120>RAB23 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2280
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 1
atgatatact ttattagaat aatcatgggc cagactggga agaaatctga gaagggacca 60
gtttgttggc ggaagcgtgt aaaatcagag tacatgcgac tgagacagct caagaggttc 120
agacgagctg atgaagtaaa gagtatgttt agttccaatc gtcagaaaat tttggaaaga 180
acggaaatct taaaccaaga atggaaacag cgaaggatac agcctgtgca catcctgact 240
tctgtgagct cattgcgcgg gactagggag tgttcggtga ccagtgactt ggattttcca 300
acacaagtca tcccattaaa gactctgaat gcagttgctt cagtacccat aatgtattct 360
tggtctcccc tacagcagaa ttttatggtg gaagatgaaa ctgttttaca taacattcct 420
tatatgggag atgaagtttt agatcaggat ggtactttca ttgaagaact aataaaaaat 480
tatgatggga aagtacacgg ggatagagaa tgtgggttta taaatgatga aatttttgtg 540
gagttggtga atgcccttgg tcaatataat gatgatgacg atgatgatga tggagacgat 600
cctgaagaaa gagaagaaaa gcagaaagat ctggaggatc accgagatga taaagaaagc 660
cgcccacctc ggaaatttcc ttctgataaa atttttgaag ccatttcctc aatgtttcca 720
gataagggca cagcagaaga actaaaggaa aaatataaag aactcaccga acagcagctc 780
ccaggcgcac ttcctcctga atgtaccccc aacatagatg gaccaaatgc taaatctgtt 840
cagagagagc aaagcttaca ctcctttcat acgcttttct gtaggcgatg ttttaaatat 900
gactgcttcc tacatcgtaa gtgcaattat tcttttcatg caacacccaa cacttataag 960
cggaagaaca cagaaacagc tctagacaac aaaccttgtg gaccacagtg ttaccagcat 1020
ttggagggag caaaggagtt tgctgctgct ctcaccgctg agcggataaa gaccccacca 1080
aaacgtccag gaggccgcag aagaggacgg cttcccaata acagtagcag gcccagcacc 1140
cccaccatta atgtgctgga atcaaaggat acagacagtg atagggaagc agggactgaa 1200
acggggggag agaacaatga taaagaagaa gaagagaaga aagatgaaac ttcgagctcc 1260
tctgaagcaa attctcggtg tcaaacacca ataaagatga agccaaatat tgaacctcct 1320
gagaatgtgg agtggagtgg tgctgaagcc tcaatgttta gagtcctcat tggcacttac 1380
tatgacaatt tctgtgccat tgctaggtta attgggacca aaacatgtag acaggtgtat 1440
gagtttagag tcaaagaatc tagcatcata gctccagctc ccgctgagga tgtggatact 1500
cctccaagga aaaagaagag gaaacaccgg ttgtgggctg cacactgcag aaagatacag 1560
ctgaaaaagg acggctcctc taaccatgtt tacaactatc aaccctgtga tcatccacgg 1620
cagccttgtg acagttcgtg cccttgtgtg atagcacaaa atttttgtga aaagttttgt 1680
caatgtagtt cagagtgtca aaaccgcttt ccgggatgcc gctgcaaagc acagtgcaac 1740
accaagcagt gcccgtgcta cctggctgtc cgagagtgtg accctgacct ctgtcttact 1800
tgtggagccg ctgaccattg ggacagtaaa aatgtgtcct gcaagaactg cagtattcag 1860
cggggctcca aaaagcatct attgctggca ccatctgacg tggcaggctg ggggattttt 1920
atcaaagatc ctgtgcagaa aaatgaattc atctcagaat actgtggaga gattatttct 1980
caagatgaag ctgacagaag agggaaagtg tatgataaat acatgtgcag ctttctgttc 2040
aacttgaaca atgattttgt ggtggatgca acccgcaagg gtaacaaaat tcgttttgca 2100
aatcattcgg taaatccaaa ctgctatgca aaagttatga tggttaacgg tgatcacagg 2160
ataggtattt ttgccaagag agccatccag actggcgaag agctgttttt tgattacaga 2220
tacagccagg ctgatgccct gaagtatgtc ggcatcgaaa gagaaatgga aatcccttga 2280
<210> 2
<211> 759
<212> PRT
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 2
Met Ile Tyr Phe Ile Arg Ile Ile Met Gly Gln Thr Gly Lys Lys Ser
1 5 10 15
Glu Lys Gly Pro Val Cys Trp Arg Lys Arg Val Lys Ser Glu Tyr Met
20 25 30
Arg Leu Arg Gln Leu Lys Arg Phe Arg Arg Ala Asp Glu Val Lys Ser
35 40 45
Met Phe Ser Ser Asn Arg Gln Lys Ile Leu Glu Arg Thr Glu Ile Leu
50 55 60
Asn Gln Glu Trp Lys Gln Arg Arg Ile Gln Pro Val His Ile Leu Thr
65 70 75 80
Ser Val Ser Ser Leu Arg Gly Thr Arg Glu Cys Ser Val Thr Ser Asp
85 90 95
Leu Asp Phe Pro Thr Gln Val Ile Pro Leu Lys Thr Leu Asn Ala Val
100 105 110
Ala Ser Val Pro Ile Met Tyr Ser Trp Ser Pro Leu Gln Gln Asn Phe
115 120 125
Met Val Glu Asp Glu Thr Val Leu His Asn Ile Pro Tyr Met Gly Asp
130 135 140
Glu Val Leu Asp Gln Asp Gly Thr Phe Ile Glu Glu Leu Ile Lys Asn
145 150 155 160
Tyr Asp Gly Lys Val His Gly Asp Arg Glu Cys Gly Phe Ile Asn Asp
165 170 175
Glu Ile Phe Val Glu Leu Val Asn Ala Leu Gly Gln Tyr Asn Asp Asp
180 185 190
Asp Asp Asp Asp Asp Gly Asp Asp Pro Glu Glu Arg Glu Glu Lys Gln
195 200 205
Lys Asp Leu Glu Asp His Arg Asp Asp Lys Glu Ser Arg Pro Pro Arg
210 215 220
Lys Phe Pro Ser Asp Lys Ile Phe Glu Ala Ile Ser Ser Met Phe Pro
225 230 235 240
Asp Lys Gly Thr Ala Glu Glu Leu Lys Glu Lys Tyr Lys Glu Leu Thr
245 250 255
Glu Gln Gln Leu Pro Gly Ala Leu Pro Pro Glu Cys Thr Pro Asn Ile
260 265 270
Asp Gly Pro Asn Ala Lys Ser Val Gln Arg Glu Gln Ser Leu His Ser
275 280 285
Phe His Thr Leu Phe Cys Arg Arg Cys Phe Lys Tyr Asp Cys Phe Leu
290 295 300
His Arg Lys Cys Asn Tyr Ser Phe His Ala Thr Pro Asn Thr Tyr Lys
305 310 315 320
Arg Lys Asn Thr Glu Thr Ala Leu Asp Asn Lys Pro Cys Gly Pro Gln
325 330 335
Cys Tyr Gln His Leu Glu Gly Ala Lys Glu Phe Ala Ala Ala Leu Thr
340 345 350
Ala Glu Arg Ile Lys Thr Pro Pro Lys Arg Pro Gly Gly Arg Arg Arg
355 360 365
Gly Arg Leu Pro Asn Asn Ser Ser Arg Pro Ser Thr Pro Thr Ile Asn
370 375 380
Val Leu Glu Ser Lys Asp Thr Asp Ser Asp Arg Glu Ala Gly Thr Glu
385 390 395 400
Thr Gly Gly Glu Asn Asn Asp Lys Glu Glu Glu Glu Lys Lys Asp Glu
405 410 415
Thr Ser Ser Ser Ser Glu Ala Asn Ser Arg Cys Gln Thr Pro Ile Lys
420 425 430
Met Lys Pro Asn Ile Glu Pro Pro Glu Asn Val Glu Trp Ser Gly Ala
435 440 445
Glu Ala Ser Met Phe Arg Val Leu Ile Gly Thr Tyr Tyr Asp Asn Phe
450 455 460
Cys Ala Ile Ala Arg Leu Ile Gly Thr Lys Thr Cys Arg Gln Val Tyr
465 470 475 480
Glu Phe Arg Val Lys Glu Ser Ser Ile Ile Ala Pro Ala Pro Ala Glu
485 490 495
Asp Val Asp Thr Pro Pro Arg Lys Lys Lys Arg Lys His Arg Leu Trp
500 505 510
Ala Ala His Cys Arg Lys Ile Gln Leu Lys Lys Asp Gly Ser Ser Asn
515 520 525
His Val Tyr Asn Tyr Gln Pro Cys Asp His Pro Arg Gln Pro Cys Asp
530 535 540
Ser Ser Cys Pro Cys Val Ile Ala Gln Asn Phe Cys Glu Lys Phe Cys
545 550 555 560
Gln Cys Ser Ser Glu Cys Gln Asn Arg Phe Pro Gly Cys Arg Cys Lys
565 570 575
Ala Gln Cys Asn Thr Lys Gln Cys Pro Cys Tyr Leu Ala Val Arg Glu
580 585 590
Cys Asp Pro Asp Leu Cys Leu Thr Cys Gly Ala Ala Asp His Trp Asp
595 600 605
Ser Lys Asn Val Ser Cys Lys Asn Cys Ser Ile Gln Arg Gly Ser Lys
610 615 620
Lys His Leu Leu Leu Ala Pro Ser Asp Val Ala Gly Trp Gly Ile Phe
625 630 635 640
Ile Lys Asp Pro Val Gln Lys Asn Glu Phe Ile Ser Glu Tyr Cys Gly
645 650 655
Glu Ile Ile Ser Gln Asp Glu Ala Asp Arg Arg Gly Lys Val Tyr Asp
660 665 670
Lys Tyr Met Cys Ser Phe Leu Phe Asn Leu Asn Asn Asp Phe Val Val
675 680 685
Asp Ala Thr Arg Lys Gly Asn Lys Ile Arg Phe Ala Asn His Ser Val
690 695 700
Asn Pro Asn Cys Tyr Ala Lys Val Met Met Val Asn Gly Asp His Arg
705 710 715 720
Ile Gly Ile Phe Ala Lys Arg Ala Ile Gln Thr Gly Glu Glu Leu Phe
725 730 735
Phe Asp Tyr Arg Tyr Ser Gln Ala Asp Ala Leu Lys Tyr Val Gly Ile
740 745 750
Glu Arg Glu Met Glu Ile Pro
755
<210> 3
<211> 20
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 3
attacaaagg cctactatcg 20
<210> 4
<211> 20
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 4
agtcactccg gtcagaattc 20

Claims (8)

1. a kind of sgRNA, is used for gene editing.
2. a kind of sgRNA, sequence such as SEQ ID NO：3.
3. CRISPR-Cas system method that RAB23 gene is knocked out in vitro epidermal stem cells is improved a kind of, including to place Synergistic protein is introduced in chief cell, the synergistic protein ESCS-higher is by SEQ ID NO:Nucleotide sequence shown in 1 is compiled The protein of code；The sgRNA, sequence such as SEQ ID NO：Shown in 3.
4. method as claimed in claim 3, further, the synergistic protein is comprising a) or b)：
a)SEQ ID NO:The polynucleotide sequence of nucleotide sequence coded protein shown in 1；
b)SEQ ID NO:Amino acid sequence shown in 2.
5. a kind of system for carrying out gene editing using CRISPR/Cas9 in epidermal stem cells, it is characterised in that the system Including：(1) for expressing SEQ ID NO：The plasmid of ESCS-higher described in 1；(2) expression that sgRNA is already inserted into The plasmid of PX330 can express sgRNA and cas9.
6. system as claimed in claim 5, it is characterised in that：(1) plasmid can be imported into advance in gene editing cell, After screening obtains positive cell, then it is transferred to the plasmid of (2).
7. purposes of the system of claim 5 in the reagent that preparation is used for epidermal stem cells gene editing.
8. purposes of the gRNA as claimed in claim 2 in preparation in epidermal stem cells and in the reagent of progress RAB23 knockout.
CN201810830035.6A 2018-07-25 2018-07-25 Rab23 gene knockout in epidermal stem cells by using CRISPR-Cas system Active CN108893473B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810830035.6A CN108893473B (en) 2018-07-25 2018-07-25 Rab23 gene knockout in epidermal stem cells by using CRISPR-Cas system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810830035.6A CN108893473B (en) 2018-07-25 2018-07-25 Rab23 gene knockout in epidermal stem cells by using CRISPR-Cas system

Publications (2)

Publication Number Publication Date
CN108893473A true CN108893473A (en) 2018-11-27
CN108893473B CN108893473B (en) 2020-06-19

Family

ID=64352039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810830035.6A Active CN108893473B (en) 2018-07-25 2018-07-25 Rab23 gene knockout in epidermal stem cells by using CRISPR-Cas system

Country Status (1)

Country Link
CN (1) CN108893473B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111849987A (en) * 2020-07-29 2020-10-30 华农（肇庆）生物产业技术研究院有限公司 Construction method and application of VIPERIN function-deficient cell line

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102643819A (en) * 2012-04-25 2012-08-22 中国人民解放军第四军医大学 ShRNA of Rab23 and ientiviral vector and applications thereof
CN107619829A (en) * 2017-10-14 2018-01-23 洛阳轩智生物科技有限公司 The method for carrying out GINS2 gene knockouts to mescenchymal stem cell using CRISPR cas systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102643819A (en) * 2012-04-25 2012-08-22 中国人民解放军第四军医大学 ShRNA of Rab23 and ientiviral vector and applications thereof
CN107619829A (en) * 2017-10-14 2018-01-23 洛阳轩智生物科技有限公司 The method for carrying out GINS2 gene knockouts to mescenchymal stem cell using CRISPR cas systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI: "PREDICTED: Homo sapiens enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), transcript variant X1, mRNA", 《NCBI XM_017011817.2》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111849987A (en) * 2020-07-29 2020-10-30 华农（肇庆）生物产业技术研究院有限公司 Construction method and application of VIPERIN function-deficient cell line

Also Published As

Publication number Publication date
CN108893473B (en) 2020-06-19

Similar Documents

Publication Publication Date Title
CN108707604B (en) CNE10 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
CN108913691A (en) Card3 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
CN108715850A (en) GING2 gene knockouts are carried out using CRISPR-Cas systems in epidermal stem cells
EP3121196B1 (en) Wnt family-derived peptides and use thereof
Bradley et al. A soluble form of Wnt-1 protein with mitogenic activity on mammary epithelial cells
Collo et al. A new isoform of the laminin receptor integrin alpha 7 beta 1 is developmentally regulated in skeletal muscle.
TW201923637A (en) Identify new antigens using hotspots
KR930702535A (en) Antibodies in which the frameworks are mutated and methods for their preparation
GEP20022681B (en) Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
Engler et al. Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation.
Page et al. Topography of lactose permease from Escherichia coli.
CN114874308B (en) Nuclide-labeled inhibitory peptide and preparation method and application thereof
Chaturvedi et al. The P-loop region of Schlafen 3 acts within the cytosol to induce differentiation of human Caco-2 intestinal epithelial cells
CN114213527B (en) T cell receptor and application thereof
CN116970058B (en) Tumor neoantigen polypeptide aiming at TP53 gene R249S mutation and application thereof
CN108893473A (en) RAB23 gene knockout is carried out using CRISPR-Cas system in epidermal stem cells
Cahill et al. Isolation and characterization of rat liver mitochondrial ribosomes
Hock et al. Talin dynamics in living microinjected nonmuscle cells
Wiche et al. Competence of soluble cell extracts as microtubule assembly systems. Comparison of simian virus 40 transformed and nontransformed mouse 3T3 fibroblasts.
CN109486828A (en) A kind of gene of encoding recombinant human&#39;s interleukin 12 and its application
WO2022012198A1 (en) Tcr-t cell for killing tumors, and preparation method therefor and use thereof
Marko et al. A novel synthetic peptide polymer with cyclic RGD motifs supports serum-free attachment of anchorage-dependent cells
CN109758590A (en) A method for screening human prostate cancer tumor epitope peptides
Puré et al. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of MHC class II molecules and expression of invariant chain
NO178504C (en) Method for Preparation of Minactivin, DNA Molecule, Gene, Host, Probes, Preparations Including Probes, Reagents for Localization and Definition. of limits for tumor in histological specimens, as well as the use of DNA molecule, minactivin and preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200525

Address after: 314113 Room 101, D8 Building, 555 Pioneer Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province

Applicant after: Zhejiang Yuan Kangrui Biological Technology Co.,Ltd.

Address before: 471000 Ludu Yuefu Building 1 Unit 1-1404, South of Qianjiang Road, West of Chang Xiamen Street, Luoyang Economic and Technological Development Zone, Henan Province

Applicant before: LUOYANG XUANZHI BIOLOGICAL TECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant